Target intelligence / Profile preview

Cytochrome P450 reductase (POR)

Target
POR
Molecular classification
Enzyme, Oxidoreductase, Diflavin reductase, Electron transfer protein
01

Overview

Cytochrome P450 reductase (POR) is a membrane-bound diflavin oxidoreductase that catalyzes the transfer of electrons from NADPH to all microsomal cytochrome P450 enzymes and other endoplasmic reticulum-associated heme proteins, such as heme oxygenase. It contains both FAD and FMN cofactors within distinct domains and is essential for the activity of cytochrome P450s in the metabolism of drugs, steroids, lipids, and xenobiotics. In humans, the POR gene is located on chromosome 7q11.23. Structural flexibility, enabled by hinge regions between domains, allows POR to interact with multiple cytochrome P450 isoforms and deliver electrons sequentially, facilitating the catalytic activities of these enzymes in detoxification and biosynthetic processes. Mutations in POR can cause disorders including altered steroidogenesis, skeletal malformations, and atypical drug responses due to changes in cytochrome P450–mediated metabolism

Other names
NADPH–cytochrome P450 reductaseNADPH:ferrihemoprotein oxidoreductaseNADPH:hemoprotein oxidoreductaseNADPH:P450 oxidoreductaseP450 reductasePORCPRCYPOR
02

Mechanism of action

Facilitates electron transfer from NADPH to microsomal cytochrome P450 enzymes and other heme proteins, enabling enzymatic activity such as hydroxylation, demethylation, and epoxidation in xenobiotic and endobiotic metabolism

03

Biological functions

Electron transferDrug metabolismSteroid biosynthesisDetoxificationOxidative stress response
04

Disease associations

Disorders of steroidogenesisCongenital adrenal hyperplasiaAntley-Bixler syndromeCancerAltered drug metabolism
05

Safety considerations

Genetic mutations can lead to combined deficiencies in steroidogenic cytochrome P450 enzymes, causing adrenal and gonadal dysfunctionAltered POR activity can result in unpredictable drug metabolism, drug-drug interactions, and adverse effectsCertain POR mutations are linked to Antley-Bixler syndrome (skeletal and genital malformations)
06

Interacting drugs

No drugs directly target POR as a therapeutic agent, but it is essential for the metabolism of a wide range of drugs by cytochrome P450 enzymes, including but not limited to warfarin, statins, antidepressants, anticonvulsants, chemotherapeutics, and steroid hormones
07

Biomarkers

POR gene mutations (for congenital disorders)POR activity or expression levels (for predicting or monitoring metabolism capacity in pharmacogenomics)

Beyond the preview

Go deeper on Cytochrome P450 reductase (POR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 reductase (POR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call